CTCBIO INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,250 KRW | +1.85% |
|
+3.00% | -22.90% |
| 04-24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| 03-21 | CTCBIO Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 154,210 | 116,133 | 160,165 | 211,563 | 150,625 | 255,824 |
| Enterprise Value (EV) 1 | 209,885 | 169,708 | 215,786 | 244,524 | 166,233 | 266,434 |
| P/E ratio | -15.8 x | -8.45 x | -7.88 x | -27.5 x | 22.3 x | -16.4 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.11 x | 0.85 x | 1.23 x | 1.51 x | 0.91 x | 1.86 x |
| EV / Revenue | 1.52 x | 1.25 x | 1.66 x | 1.74 x | 1.01 x | 1.93 x |
| EV / EBITDA | -225 x | 68.8 x | -3,512 x | 73.1 x | 9.02 x | 195 x |
| EV / FCF | -28.7 x | 57.8 x | -18.7 x | -313 x | 12.4 x | 46.5 x |
| FCF Yield | -3.48% | 1.73% | -5.36% | -0.32% | 8.1% | 2.15% |
| Price to Book | 1.78 x | 1.55 x | 2.1 x | 2.49 x | 1.57 x | 3.39 x |
| Nbr of stocks (in thousands) | 19,038 | 19,038 | 20,774 | 23,351 | 23,909 | 23,909 |
| Reference price 2 | 8,100 | 6,100 | 7,710 | 9,060 | 6,300 | 10,700 |
| Announcement Date | 3/21/19 | 3/18/20 | 3/17/21 | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 138,400 | 136,124 | 130,032 | 140,318 | 165,206 | 137,878 |
| EBITDA 1 | -930.9 | 2,467 | -61.44 | 3,344 | 18,423 | 1,368 |
| EBIT 1 | -5,856 | -3,856 | -5,877 | -2,938 | 11,717 | -4,578 |
| Operating Margin | -4.23% | -2.83% | -4.52% | -2.09% | 7.09% | -3.32% |
| Earnings before Tax (EBT) 1 | -6,848 | -13,048 | -22,738 | -7,687 | -37.6 | -15,715 |
| Net income 1 | -9,061 | -13,739 | -19,458 | -7,318 | 6,752 | -15,588 |
| Net margin | -6.55% | -10.09% | -14.96% | -5.22% | 4.09% | -11.31% |
| EPS 2 | -513.9 | -722.0 | -978.0 | -329.3 | 283.0 | -652.0 |
| Free Cash Flow 1 | -7,302 | 2,934 | -11,563 | -780.8 | 13,460 | 5,724 |
| FCF margin | -5.28% | 2.16% | -8.89% | -0.56% | 8.15% | 4.15% |
| FCF Conversion (EBITDA) | - | 118.94% | - | - | 73.06% | 418.32% |
| FCF Conversion (Net income) | - | - | - | - | 199.35% | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/21/19 | 3/18/20 | 3/17/21 | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 55,675 | 53,574 | 55,621 | 32,961 | 15,607 | 10,610 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -59.81 x | 21.72 x | -905.3 x | 9.856 x | 0.8472 x | 7.754 x |
| Free Cash Flow 1 | -7,302 | 2,934 | -11,563 | -781 | 13,460 | 5,724 |
| ROE (net income / shareholders' equity) | -11.3% | -17% | -30.7% | -9.61% | 6.08% | -16.3% |
| ROA (Net income/ Total Assets) | -1.91% | -1.27% | -2.02% | -1.06% | 4.11% | -1.62% |
| Assets 1 | 474,677 | 1,078,057 | 963,248 | 688,325 | 164,180 | 959,373 |
| Book Value Per Share 2 | 4,563 | 3,926 | 3,674 | 3,641 | 4,014 | 3,156 |
| Cash Flow per Share 2 | 243.0 | 802.0 | 586.0 | 318.0 | 1,002 | 1,030 |
| Capex 1 | 1,498 | 2,215 | 1,924 | 1,674 | 3,173 | 1,885 |
| Capex / Sales | 1.08% | 1.63% | 1.48% | 1.19% | 1.92% | 1.37% |
| Announcement Date | 3/21/19 | 3/18/20 | 3/17/21 | 3/18/22 | 3/23/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -22.90% | 142M | |
| -14.44% | 76.62B | |
| +14.56% | 8.4B | |
| +25.88% | 3.76B | |
| +18.24% | 1.65B | |
| -8.82% | 1.53B | |
| -22.51% | 1.3B | |
| -3.32% | 1.25B | |
| -10.11% | 1.19B | |
| +4.27% | 1.1B |
- Stock Market
- Equities
- A060590 Stock
- Financials CTCBIO Inc.
